Abstract
The COVID-19 pandemic has affected millions and congested healthcare systems globally. Hence an objective severity assessment is crucial in making therapeutic decisions judiciously. Computed Tomography (CT)-scans can provide demarcating features to identify severity of pneumonia —commonly associated with COVID-19—in the affected lungs. Here, a quantitative severity assessing chest CT image feature is demonstrated for COVID-19 patients. We incorporated 509 CT images from 101 diagnosed and expert-annotated cases (age 20-90, 60% males) in the study collected from a multi-center Italian database1 sourced from 41 radio-diagnostic centers. Lesions in the form of opacifications, crazy-paving patterns, and consolidations were segmented. The severity determining feature —Lnorm was quantified and established to be statistically distinct for the three —mild, moderate, and severe classes (p-value<0.0001). The thresholds of Lnorm for a 3-class classification were determined based on the optimum sensitivity/specificity combination from Receiver Operating Characteristic (ROC) analyses. The feature Lnorm classified the cases in the three severity categories with 86.88% accuracy. ‘Substantial’ to ‘almost-perfect’ intra-rater and inter-rater agreements were achieved involving expert (manual segmentation) and non-expert (graph-cut and deep-learning based segmentation) labels (κ-score 0.79-0.97). We trained several machine learning classification models and showed Lnorm alone has a superior diagnostic accuracy over standard image intensity and texture features. Classification accuracy was further increased when Lnorm was used for 2-class classification i.e. to delineate the severe cases from non-severe ones with a high sensitivity (97.7%), and specificity (97.49%). Therefore, key highlights of the COVID-19 severity assessment feature are high accuracy, low dependency on expert availability, and wide utility across different CT-imaging centers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used in the article has been published as an open-source database and hence IRB approvals are not needed. The source has been duly cited in the manuscript.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The number of patient data and radio-diagnostic centers increased; Automated detection of lung lesions with deep learning added; updated review of literature; Fig 2, Fig 3, Fig 5, Fig 7 modified; Fig 6 added; New table 1 added; Table 2 updated; Supplemental files updated for better assessment of ground truth and better explanation of methods.
Data Availability
All data and codes can be made available upon request.
